AI is accelerating everything, from how fast an individual can make a grocery list to the speed at which drug discovery timelines play out for pharmaceutical manufacturers. However, many in the healthcare industry are clinging to the old R&D playbook, and legacy strategies will no longer cut it in the time of automation and machine learning. The shift is structural, so it can’t be gradual. Those who remain slow and steady will not win this race.
As AI and personalized medicine reshape the healthcare landscape, pharmaceutical and biotech companies can no longer afford the luxury of cautious, incremental R&D strategies. Only by adopting a venture-building mindset that prioritizes rapid experimentation and structural innovation will they remain competitive in an era that rewards speed over certainty.
When “watch and learn” becomes a liability
Many healthcare organizations have been caught in a “wait and see” trap. This tactic may feel strategic, but it’s actually just slow. By avoiding experimentation, organizations are already behind those that have chosen to act. Inaction comes at a cost, be it talent, intellectual property, or market position. The best time to run experiments was ten years ago. The second-best time is right now.
The forces rewriting the rules of healthcare innovation are moving quickly. AI and machine learning are dramatically compressing drug discovery timelines and changing competitive moats. Personalized medicine is fragmenting mass-market models and demanding new operating structures. The continuous and rapid regulatory evolution has left most internal teams scrambling to catch up as agencies move faster than anticipated. The result of these forces requires a structural response — not a tactical one.
Venture building in a healthcare context
Venture building is a structured engine for creating startups that solve real-world problems. Beyond solving urgent industry challenges, venture building programs offer something equally valuable: they dramatically accelerate organizational learning. Because startups operate with fewer bureaucratic constraints and are structurally motivated to create rather than protect, they can move from hypothesis to experiment to insight much faster than established organizations. That speed compounds — each cycle of experimentation builds the knowledge base for the next, creating a continuous cycle of innovation that legacy structures just can’t replicate.
When executed intentionally, venture building becomes a systematic path to generating a portfolio of companies that address real market gaps and generate meaningful value not just to end users, but to the parent organization, its partners, and the broader ecosystem it operates within.
In practice, this often means working alongside specialized external venture builders to surface unmet needs and identify the strategic white spaces where a new company can make a genuine impact. The goal is finding the intersection between market urgency and organizational capability, then building toward it through business model experimentation that would be too slow, too risky, or too structurally awkward to pursue internally.
Speed over certainty
Venture-built startups can champion speed over certainty. Historically in healthcare, the established process was to wait for that certainty before committing resources because failures can cost hundreds of millions of dollars. Startups, on the other hand, have the agility and ability to run more experiments faster and extract learning from each one, regardless of the outcome.
This is what speed over certainty actually means. Startups aren’t abandoning scientific standards or rushing products through validation. They’re recognizing that in a landscape reshaped by AI and personalized medicine, the ability to generate and test hypotheses quickly has become a core competitive capability.
Venture-built startups are structurally optimized for exactly this. Unburdened by the legacy processes and preservation instincts that slow large organizations down, they can run parallel experiments across business models, therapeutic approaches, and delivery mechanisms simultaneously. A portfolio of ventures moves in parallel, multiplying the organization’s surface area for discovery.
The forces reshaping healthcare are not on a timeline that accommodates organizational hesitation. Venture building is not a silver bullet, and framing it as one would be a disservice. It requires real structural commitment, genuine leadership courage, and the willingness to look different from the rest of the industry for long enough that it starts to pay off. None of that is easy inside organizations built for a different era.
But the alternative — continuing to treat cautious incrementalism as a viable strategy while the competitive landscape restructures around you — carries risks that dwarf the discomfort of transformation. The experiment you don’t run today doesn’t just represent a missed learning opportunity. In a market that rewards speed, it becomes the advantage your competitor is building instead.
About Elliot Parker
Elliott Parker is CEO of Alloy Partners, a venture builder that co-creates advantaged startups with corporations and entrepreneurs. He previously launched dozens of startups at High Alpha, the pioneering venture studio, and helped Fortune 100 firms design and execute growth strategies at Clayton Christensen’s firm Innosight. Elliott is passionate about helping big organizations move fast and think boldly—and wrote The Illusion of Innovation to inspire transformation through bold experimentation.Thanks
